Potential blood test for colon cancer risk

Johns Hopkins scientists have found a way to predict with a simple blood test which people may be at higher than normal risk for the most common form of colon cancer. The research, described in the March 14, 2003 issue of Science, focuses on genetic "red flags" housed not in the sequence of the DNA building blocks themselves, but in other subtle modifications made to the genetic code.

"We hope these findings will have the ability to identify people at increased risk for colon cancer, follow them closely and prevent disease or at least catch it early, similar to the approach doctors use in identifying patients at risk of heart disease," says Andrew P. Feinberg, M.D., King Fahd Professor of Medicine in the Kimmel Cancer Center at Johns Hopkins.

At present, the genetic marker blood tests are for research purposes only, Feinberg emphasized. "More efficient tests will take several more years at least to develop," said Feinberg, who with Hengmi Cui, Ph.D., and Marcia Cruz-Correa, M.D., Ph.D., led the study. "We also need to follow patients over time to see if they develop cancer after the test is positive," he added.

Prior research at Hopkins and elsewhere has identified genetic mutations linked specifically to hereditary forms of colon cancer. The genetic information uncovered in this study applies to the much more common forms of colon cancer that occur sporadically among the general population. An estimated 155,000 cases are diagnosed annually in the United States.

Earlier work also by the Feinberg team has shown that a form of gene silencing called loss of imprinting (LOI) in a growth-promoting gene called IGF2 (for insulin like growth factor) is one of the first genetic defects that happen in up to 40 percent of colon cancers. In the new study, the researchers found IGF2-related LOI present in blood samples as well as in colon tissue.

In an analysis of blood samples from 172 individuals who had a colonoscopy, a t

Contact: Vanessa Wasta
Johns Hopkins Medical Institutions

Page: 1 2 3

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
3. Potential cause of arthritis discovered
4. Potential of regenerative medicine explored
5. Potential therapy reported for children, adults with end-stage liver disease
6. Potential allergy vaccine boosts hope for sufferers
7. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:

(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
Cached News: